The menopause health gap is a pressing issue that affects millions of women worldwide, yet it remains largely hidden from public discourse. Vaginal dryness, a common symptom of menopause, is experienced by over half of women, yet only a fraction of them ever discuss it with their healthcare provider. This silence perpetuates an injustice and presents an opportunity for innovation in women's health.
As an entrepreneur, I've always been drawn to solving problems that matter. When I delved into women's health, I noticed a stark disparity in innovation. While there was a wealth of research and products focused on fertility and pregnancy, the same couldn't be said for menopause and its associated symptoms. This realization sparked a journey that led me to co-found Biolae, a company dedicated to addressing the unmet needs of women during perimenopause.
One of the most significant challenges in women's health is the lack of clinically validated, non-hormonal solutions for perimenopause symptoms. Vaginal dryness, for instance, is a prevalent issue that often goes unaddressed due to the absence of suitable products. This gap in the market not only affects women's quality of life but also highlights the need for a paradigm shift in how we approach women's health.
Biolae's mission is to set a new standard for women's health products. We believe that clinical validity should be non-negotiable, and our products are backed by gold-standard clinical trials, dosed at therapeutic levels, and independently tested for purity and potency. By establishing a Scientific Advisory Board, we ensure that our products meet the highest evidence standards.
As an entrepreneur with a consumer brand background, I understand the importance of connecting with women on a deeper level. Healthcare has traditionally prioritized efficacy over design, experience, and community. However, I believe these aspects are not mutually exclusive. Biolae aims to prove that by creating products that not only work but also resonate with women on a personal level.
Our upcoming launch of Australia's first TGA-listed hyaluronic acid pessary is a testament to our commitment to innovation. This product, developed over three years, represents a significant milestone in our journey. Launching a first-to-market medical device in a personal category comes with a sense of responsibility, and I take that role seriously.
Vaginal dryness is often associated with menopause, but it's a symptom that affects women in various stages of life. It can occur postpartum, during stressful periods, or as a side effect of certain medications. By pulling vaginal dryness out from under the menopause umbrella, we aim to educate women and normalize a conversation that has long been taboo.
The menopause conversation has evolved, but vaginal dryness remains a silent issue. This gap between prevalence and discussion is where we believe the real impact lies. By addressing this symptom, we can empower women and drive cultural change.
Launching a first-to-market medical device in consumer health is a rare opportunity, and we embrace the challenge of building in underserved spaces. Our campaign, Not-So-Dry July, is designed to educate women and make the conversation less intimidating. We believe that humor, when used thoughtfully, can break down stigma and encourage open dialogue.
Looking ahead, our next big frontier is the pharmacy. By entering this space, we aim to reshape how retailers think about menopause and the role of these products in women's lives. The menopause shelf's placement in stores reflects the traditional undervaluing of this category, and we're determined to change that.
The journey of Biolae has been anything but linear. We've faced setbacks, pivoted, and navigated moments of uncertainty, but it's all part of the startup experience. As we continue to innovate in women's health, I'm excited about the future. With the attention women's health is finally receiving, there are countless opportunities to address unmet needs, and that's a thrilling prospect.
